TITLE

Mylan Issues $300M in Add-On HY Deal

AUTHOR(S)
Sheahan, Matthew
PUB. DATE
August 2010
SOURCE
High Yield Report;8/2/2010, Vol. 21 Issue 31, p35
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Mylan has priced 300 million U.S. dollars in junk bonds in an add-on offering, proceeds of which will be used to finance an acquisition.
ACCESSION #
52683265

 

Related Articles

  • Mylan Plans $300M Add-On HY Deal. Sheahan, Matthew // High Yield Report;8/2/2010, Vol. 21 Issue 31, p33 

    The article unveils the plan of pharmaceutical manufacturer Mylan to launch 300 million U.S. dollars in an add-on round of high yield bonds.

  • Mylan, Frontier Oil Plan HY Drive-Bys. Sheahan, Matthew // High Yield Report;11/15/2010, Vol. 21 Issue 46, p40 

    The article offers information on junk bond issues by Mylan and Frontier Oil.

  • Mylan to Fill $1B Bond Prescription. Sheahan, Matthew // High Yield Report;5/10/2010, Vol. 21 Issue 19, p6 

    The article reports on the plan of pharmaceutical manufacturer Mylan to issue 1 billion dollars in junk bonds through a two-tranche offering and use the funds to repay term loan debt.

  • Mylan Prices Upsized $1.25B HY Deal. Sheahan, Matthew // High Yield Report;5/17/2010, Vol. 21 Issue 20, p13 

    The article talks about the 1.25 billion U.S. dollars in high-yield bonds that Mylan issued to settle term loans of 1 billion U.S. dollars and finance corporate expenses.

  • Health-care update.  // Dow Theory Forecasts;3/9/2015, Vol. 71 Issue 10, p1 

    The article focuses on the business performance of the research company Mylan Inc. which shows that earnings per share for the December quarter increased 35% to $1.05 and revenue increased 15% to $2.08 billion.

  • CORRECTION:.  // Secured Lender;Jan/Feb2010, Vol. 66 Issue 1, p16 

    A correction to an article that erroneously placed Mylan among companies most likely to go bankrupt in 2010 is presented.

  • A First for Mylan-Biocon Joint Venture.  // Chain Drug Review;12/16/2013, Vol. 35 Issue 20, p99 

    The article reports that Mylan Inc. and Biocon have got approval for the drug trastuzumab from the Drug Controller General of India.

  • MYLAN. Investor's Business Daily // Investors Business Daily;10/31/2014, pA02 

    The article reports on the third quarter (Q3) profit of Mylan.

  • Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal. AMY REEVES // Investors Business Daily;10/31/2014, p00 

    The article reports on the success of drugmaker Mylan to beat third-quarter estimates.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics